ROCKVILLE, Md., May 24, 2024
/PRNewswire/ -- AbelZeta Pharma, Inc. ("AbelZeta" or the
"Company"), a global clinical-stage biopharmaceutical company
focused on the discovery and development of innovative and
proprietary cell-based therapeutic products, today announced that
data from its C-CAR031 study has been published in an abstract
available on the 2024 American Society of Clinical Oncology's
(ASCO) official website, in connection with the Company's oral
presentation at the ASCO Annual Meeting taking place
in Chicago May 31 to June 4, 2024. The presentation will
share safety and preliminary efficacy data for C-CAR031 across 24
patients with hepatocellular carcinoma (HCC). Abstracts are
available at meetings.ASCO.org.
Details of the oral presentation are as follows:
Abstract Title: "Phase I study of C-CAR031, a
GPC3-specific TGFβRIIDN armored autologous CAR-T, in patients with
advanced hepatocellular carcinoma (HCC)."
Abstract Number: 4019
Session Type and Title: Rapid Oral
Abstract – Gastrointestinal
Cancer – Gastroesophageal, Pancreatic, and
Hepatobiliary
Session Date and Time: 6/3/2024; 9:45 AM-11:15 AM CDT
About C-CAR031
C-CAR031 is an autologous, armored GPC3-targeting chimeric
antigen receptor T-Cell (CAR-T) therapy, being studied in the
treatment of HCC. It is based on a novel GPC3-targeting CAR-T
designed by AstraZeneca (LSE/STO/Nasdaq: AZN) using their
transforming growth factor-beta receptor II dominant negative
(TGFβRIIDN) armoring discovery platform and is manufactured by
AbelZeta in China. C-CAR031 is
being developed in China under a
co-development agreement
between AbelZeta and AstraZeneca.1
About AbelZeta Pharma, Inc.
AbelZeta is a global clinical-stage biopharmaceutical company
with centers of excellence in Rockville,
Maryland and Shanghai,
China. AbelZeta is focusing on developing innovative and
proprietary cell-based therapeutic products and is committed to
ushering in bespoke treatments that harness the body's own immune
system to fight against hematological malignancies and solid
tumors, as well as inflammatory and immunological diseases.
AbelZeta advances research and development in its own GMP
facilities at its centers of excellence for early-stage clinical
studies, with a pipeline comprised of CAR-T and TIL therapies.
Forward-Looking Statements
Statements in this communication relating to plans, strategies,
specific activities, and other statements that are not descriptions
of historical facts are forward-looking statements. Forward-looking
information is inherently subject to risks and uncertainties,
and actual results could differ materially from those
currently anticipated due to a number of factors, which include any
risks detailed from time to time in the Company's reports. Such
statements are based on the management's current beliefs and
expectations and are subject to significant risks and uncertainties
outside of management and the Company's control. Given these
uncertainties, you should not place undue reliance on these
forward-looking statements, which speak only as of the date hereof.
Except as otherwise required by law, the Company does not undertake
any obligation, and expressly disclaims any obligation, to update,
alter or otherwise revise any forward-looking statements, whether
written or oral, that may be made from time to time, whether as a
result of new information, future events or otherwise.
Company Contact:
Sarah Kelly
Director of Communications
AbelZeta Pharma, Inc.
+1 (240) 552 5870
sarah.kelly@abelzeta.com
www.abelzeta.com
References
1. AbelZeta. AbelZeta Pharma Announces Agreement with
AstraZeneca to Co-Develop a novel Glypican 3 (GPC3) Armored CAR-T
Therapy in China. December 2023.
https://www.abelzeta.com/abelzeta-pharma-announces-agreement-with-astrazeneca-to-co-develop-a-novel-glypican-3-gpc3-armored-car-t-therapy-in-china/
View original content to download
multimedia:https://www.prnewswire.com/news-releases/abelzeta-announces-publication-of-abstract-for-asco-2024-annual-meeting-302155035.html
SOURCE AbelZeta Pharma, Inc.